2022年12月最新中科院JCR期刊分区表数据（升级版）已经更新，欢迎查询！ 如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | Molecular Cancer MOL CANCER LetPub评分 8.5
60人评分
我要评分
声誉 8.6 影响力 8.2 速度 8.7 | |||||||||||||||||||||||||
| 期刊ISSN | 1476-4598 | 微信扫码收藏此期刊 | ||||||||||||||||||||||||
| 2021-2022最新影响因子 （数据来源于搜索引擎） | 41.444 点击查看影响因子趋势图 | |||||||||||||||||||||||||
| 2021-2022自引率 | 1.80%点击查看自引率趋势图 | |||||||||||||||||||||||||
| h-index | 103 | |||||||||||||||||||||||||
| CiteScore |
| |||||||||||||||||||||||||
| 期刊简介 | Molecular Cancer promotes the exchange of ideas, concepts and findings in any area of cancer and related biomedical science, from a molecular point of view. Molecular Cancer is interested in articles from basic, translational and clinical research, opening new avenues for the understanding, prevention, diagnosis and treatment of cancer. Topics of interest include, but are not limited to: cell and tumor biology, angiogenesis, animal models, metastasis, cancer antigens and the immune response to them, cellular signalling and molecular biology, epidemiology, genetic and molecular profiling of cancer and molecular targets, cancer stem cells, DNA damage and repair, cell cycle, apoptosis, molecular virology and vaccine- and antibody-based cancer therapies. | |||||||||||||||||||||||||
| 期刊官方网站 | http://molecular-cancer.biomedcentral.com | |||||||||||||||||||||||||
| 期刊投稿网址 | https://submission.nature.com/new-submission/12943/3 | |||||||||||||||||||||||||
| 作者指南网址 | http://molecular-cancer.biomedcentral.com/submission-guidelines | |||||||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足Molecular Cancer的语言要求，还能让Molecular Cancer编辑和审稿人得到更好的审稿体验，让稿件最大限度地被Molecular Cancer编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||||||
| 是否OA开放访问 | Yes | |||||||||||||||||||||||||
OA期刊相关信息 | 文章处理费：需要（ GBP3170; ） 文章处理费豁免：查看说明 其他费用：没有 期刊主题关键词：oncology、tumour biology、cancer antigens 相关链接：Aims & ScopeAuthor InstructionsEditorial BoardBlind peer review | |||||||||||||||||||||||||
| 通讯方式 | BIOMED CENTRAL LTD, 236 GRAYS INN RD, FLOOR 6, LONDON, ENGLAND, WC1X 8HL | |||||||||||||||||||||||||
| 出版商 | BioMed Central | |||||||||||||||||||||||||
| 涉及的研究方向 | 医学-生化与分子生物学 | |||||||||||||||||||||||||
| 出版国家或地区 | ENGLAND | |||||||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||||||
| 出版周期 | Monthly | |||||||||||||||||||||||||
| 出版年份 | 2002 | |||||||||||||||||||||||||
| 年文章数 | 129点击查看年文章数趋势图 | |||||||||||||||||||||||||
| Gold OA文章占比 | 99.55% | |||||||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 62.02% | |||||||||||||||||||||||||
| WOS期刊SCI分区 （ 2021-2022年最新版） | WOS分区等级：1区
| |||||||||||||||||||||||||
| 中科院《国际期刊预警 名单（试行）》名单 | 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2021年01月发布的2020版：不在预警名单中 | |||||||||||||||||||||||||
| 中科院SCI期刊分区 （ 2022年12月最新升级版） | 点击查看中科院SCI期刊分区趋势图
| |||||||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月基础版） |
| |||||||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月升级版） |
| |||||||||||||||||||||||||
| 中科院SCI期刊分区 （ 2020年12月旧的升级版） |
| |||||||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) Directory of Open Access Journals (DOAJ) | |||||||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1476-4598%5BISSN%5D | |||||||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 平均2月 | |||||||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 约50% | |||||||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在Molecular Cancer顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 | |||||||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers Author: Li, Bo; Chen, Hui; Yang, Shaohua; Chen, Feng; Xu, Liangliang; Li, Yan; Li, Mingzhe; Zhu, Chengming; Shao, Fangyuan; Zhang, Xinhua; Deng, Chuxia; Zeng, Leli; He, Yulong; Zhang, Changhua Journal: MOLECULAR CANCER. 2023; Vol. 22, Issue 1, pp. -. DOI: 10.1186/s12943-023-01770-6 PubMed DOI |
| 2. | A novel protein encoded by circINSIG1 reprograms cholesterol metabolism by promoting the ubiquitin-dependent degradation of INSIG1 in colorectal cancer Author: Xiong, Li; Liu, Hua-shan; Zhou, Chi; Yang, Xin; Huang, Liang; Jie, Hai-qing; Zeng, Zi-wei; Zheng, Xiao-bin; Li, Wen-xin; Liu, Zhan-zhen; Kang, Liang; Liang, Zhen-xing Journal: MOLECULAR CANCER. 2023; Vol. 22, Issue 1, pp. -. DOI: 10.1186/s12943-023-01773-3 PubMed DOI |
| 3. | Tumor-secreted exosomal miR-141 activates tumor-stroma interactions and controls premetastatic niche formation in ovarian cancer metastasis Author: Mo, Yulan; Leung, Leanne L.; Mak, Celia S. L.; Wang, Xueyu; Chan, Wai-Sun; Hui, Lynn M. N.; Tang, Hermit W. M.; Siu, Michelle K. Y.; Sharma, Rakesh; Xu, Dakang; Tsui, Stephen K. W.; Ngan, Hextan Y. S.; Yung, Mingo M. H.; Chan, Karen K. L.; Chan, David W. W. Journal: MOLECULAR CANCER. 2023; Vol. 22, Issue 1, pp. -. DOI: 10.1186/s12943-022-01703-9 PubMed DOI |
| 4. | Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma Author: Liu, Zhuohao; Zhou, Jiayi; Yang, Xinzhi; Liu, Yuchen; Zou, Chang; Lv, Wen; Chen, Cheng; Cheng, Kenneth King-yip; Chen, Tao; Chang, Lung-Ji; Wu, Dinglan; Mao, Jie Journal: MOLECULAR CANCER. 2023; Vol. 22, Issue 1, pp. -. DOI: 10.1186/s12943-022-01711-9 PubMed DOI |
| 5. | CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer Author: Xing, Fei; Gao, Hongli; Chen, Guanglei; Sun, Lisha; Sun, Jiayi; Qiao, Xinbo; Xue, Jinqi; Liu, Caigang Journal: MOLECULAR CANCER. 2023; Vol. 22, Issue 1, pp. -. DOI: 10.1186/s12943-023-01716-y PubMed DOI |
| 6. | Crosstalk between 5-methylcytosine and N-6-methyladenosine machinery defines disease progression, therapeutic response and pharmacogenomic landscape in hepatocellular carcinoma Author: Tian, Yu; Xiao, Haijuan; Yang, Yanhui; Zhang, Pingping; Yuan, Jiahui; Zhang, Wei; Chen, Lijie; Fan, Yibao; Zhang, Jinze; Cheng, Huan; Deng, Tingwei; Yang, Lin; Wang, Weiwei; Chen, Guoyong; Wang, Peiqin; Gong, Peng; Niu, Xing; Zhang, Xianbin Journal: MOLECULAR CANCER. 2023; Vol. 22, Issue 1, pp. -. DOI: 10.1186/s12943-022-01706-6 PubMed DOI |
| 7. | Advancements in nanoparticle-based treatment approaches for skin cancer therapy Author: Zeng, Leli; Gowda, B. H. Jaswanth; Ahmed, Mohammed Gulzar; Abourehab, Mohammed A. S.; Chen, Zhe-Sheng; Zhang, Changhua; Li, Jia; Kesharwani, Prashant Journal: MOLECULAR CANCER. 2023; Vol. 22, Issue 1, pp. -. DOI: 10.1186/s12943-022-01708-4 PubMed DOI |
| 8. | Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer Author: Liu, Zhe; Parveen, Neha; Rehman, Urushi; Aziz, Aisha; Sheikh, Afsana; Abourehab, Mohammed A. S.; Guo, Wei; Huang, Junhao; Wang, Zhenning; Kesharwani, Prashant Journal: MOLECULAR CANCER. 2023; Vol. 22, Issue 1, pp. -. DOI: 10.1186/s12943-022-01696-5 PubMed DOI |
| 9. | CircZBTB44 promotes renal carcinoma progression by stabilizing HK3 mRNA structure Author: Li, Tushuai; Gu, Yue; Xu, Baocai; Kuca, Kamil; Zhang, Jie; Wu, Wenda Journal: MOLECULAR CANCER. 2023; Vol. 22, Issue 1, pp. -. DOI: 10.1186/s12943-023-01771-5 PubMed DOI |
| 10. | A novel polypeptide encoded by the circular RNA ZKSCAN1 suppresses HCC via degradation of mTOR Author: Song, Runjie; Ma, Shuoqian; Xu, Jiajia; Ren, Xin; Guo, Peilan; Liu, Huijiao; Li, Peng; Yin, Fan; Liu, Mei; Wang, Qiang; Yu, Lei; Liu, Jiali; Duan, Binwei; Rahman, Nafis A.; Wolczynski, Slawomir; Li, Guangming; Li, Xiangdong Journal: MOLECULAR CANCER. 2023; Vol. 22, Issue 1, pp. -. DOI: 10.1186/s12943-023-01719-9 PubMed DOI |
|
|
  | |
|
以上SCI期刊相关数据和信息来源于网络，仅供参考。
投稿状态统计： 我要评分： | |
同领域作者分享投稿经验：共4条 （包含回复） |
我来分享 |
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2023 中国: LetPub上海分公司 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960
增值电信业务经营许可证：沪B2-20211595
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦2103室
United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451
安全保密
